Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma

Abstract

Background/Aim: Primary mediastinal large Bcell lymphoma (PMLBCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20monoclonal antibody rituximab into current therapeutic regimens. Evidence, however, on the optimal time interval between consecutive chemoimmunotherapy (CIT) cycles is still scarce. This study aimed to evaluate the efficacy outcomes of the more commonly administered 3-weekly regimens to the biweekly ones in a PMLBCL patients' population, who were mostly treated with rituximab, 1302

Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era

“…Among the total population of 564 adult patients with PMLBCL, 461 consecutive patients were treated in the cooperating Hellenic and Cypriot Hematology Departments with R-CHOP or similar regimens (n = 351; mostly R-CHOP-21, R-CHOP-14 in a minority) or R-da-EPOCH (n = 110) with or without RT between 2001 and 2021, as has been previously described. 3,8,20,21 The remaining 103 patients had been treated with R-da-EPOCH, mostly without RT, representing part of the Israeli (n = 49; 2013-2019) and Turkish national experience (n = 34; 2013-2018) 22 and a Saudi Arabia single center experience (n = 20; 2015-2019). Patients were eligible for inclusion if they had presented with a clinical picture dominated by a prominent mediastinal mass and a histology report consistent with PMLBCL according to the WHO or Revised European American Lymphoma classification.…”